Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Insider Sells $89,600.00 in Stock

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) insider Thomas Gad sold 4,000 shares of the business’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $22.40, for a total value of $89,600.00. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Thomas Gad also recently made the following trade(s):

  • On Monday, June 24th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $21.77, for a total value of $87,080.00.
  • On Monday, June 10th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $22.79, for a total value of $91,160.00.
  • On Monday, June 3rd, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $20.03, for a total value of $80,120.00.
  • On Tuesday, May 28th, Thomas Gad sold 6,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $20.21, for a total value of $121,260.00.
  • On Monday, May 13th, Thomas Gad sold 6,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $20.61, for a total value of $123,660.00.
  • On Thursday, April 11th, Thomas Gad sold 250,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $25.89, for a total value of $6,472,500.00.

Shares of YMAB opened at $22.87 on Friday. The firm has a market cap of $782.02 million and a P/E ratio of -15.25. Y-mAbs Therapeutics, Inc has a 12 month low of $15.17 and a 12 month high of $31.00. The stock’s 50-day moving average is $21.82. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.30 and a quick ratio of 13.30.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Friday, May 10th. The company reported ($0.47) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.07). Equities research analysts forecast that Y-mAbs Therapeutics, Inc will post -1.95 EPS for the current fiscal year.

Several brokerages have commented on YMAB. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of Protalix Biotherapeutics in a report on Monday, June 10th. Zacks Investment Research downgraded Yatra Online from a “hold” rating to a “sell” rating in a report on Saturday, July 6th. Finally, Cowen reaffirmed a “buy” rating on shares of Ovid Therapeutics in a report on Monday, July 1st. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Y-mAbs Therapeutics presently has an average rating of “Buy” and a consensus price target of $30.80.

Institutional investors and hedge funds have recently made changes to their positions in the business. TD Asset Management Inc. lifted its holdings in Y-mAbs Therapeutics by 24.1% during the 1st quarter. TD Asset Management Inc. now owns 22,829 shares of the company’s stock worth $598,000 after buying an additional 4,432 shares during the period. Bank of America Corp DE lifted its holdings in Y-mAbs Therapeutics by 3,056.5% during the 4th quarter. Bank of America Corp DE now owns 6,029 shares of the company’s stock worth $122,000 after buying an additional 5,838 shares during the period. American International Group Inc. acquired a new position in Y-mAbs Therapeutics during the 4th quarter worth about $93,000. Barclays PLC acquired a new position in Y-mAbs Therapeutics during the 4th quarter worth about $210,000. Finally, BNP Paribas Arbitrage SA acquired a new position in Y-mAbs Therapeutics during the 1st quarter worth about $38,000. 24.80% of the stock is currently owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Further Reading: Trading Strategy Methods for Individual Investors

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.